Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol
- 31 March 2006
- journal article
- Published by Elsevier BV in Contraception
- Vol. 73 (3), 223-228
- https://doi.org/10.1016/j.contraception.2006.01.001
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptiveContraception, 2005
- Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement TherapyArchives of Internal Medicine, 2004
- Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pillBritish Journal of Clinical Pharmacology, 2002
- A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™)Fertility and Sterility, 2002
- Oral Contraceptives and the Risk of Venous ThrombosisThe New England Journal of Medicine, 2001
- Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysisBMJ, 2000
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995